News About: Pharm. Industry
Listed pharmaceutical companies’ annual sales per employee reach KRW 364.46 million
It was analyzed listed pharmaceutical companies’ annual sales per employee were KRW 364.46 million, and large companies made sales that are KRW 135 million higher than medium and small companies.
Based on the analys...
Generic companies drooling over on Lyrica’s market
A series of generics are being developed to target the Lyrica’s(pregabalin)patent expiration date for its pain indication. The number of products that were newly approved this year reaches 30 products.
Since tens of...
AZ’s headquarters inform budget cut, spreading rumors about reconstructionThe AstraZeneca’s reconstruction has been rumored.
According to the industry concerned on the 17th, the AstraZeneca’s headquarters informed the budget cut of USD 10 to 14 mill...
|
“Although the effect of rebate eradication exists, follow-up management is still needed”
The government’s authorities, such as the Ministry of Health and Welfare(MOHW), the Fair Trade Commission(FTC) and the Anti-Corruption and Civil Rights Commission(ACRC), mentioned it is important to propose fundamenta...
Will KRPIA’s confiscation lead to investigation on professors and associations?
The prosecution has been sharply investigating the Novartis’s rebate case.
After searching and seizing Novartis Korea last February and additionally 2 medical magazine companies later, the Seoul Western District Pros...
MSD & GSK only brought dishonor on NIP over their cervical cancer vaccines
The pharmaceutical companies which delayed the enforcement day to raise profits on the NIP project with cervical cancer vaccines did not earn substance, but only brought dishonor.
This is because the unit prices bid ...
Why did pharmaceutical association postpone secret voting?
Since the rebate situation has been developed, the ‘secret voting’ got also delayed. Despite a part of the industry’s opposition, the secret voting which has been conducted for 3 times so far has been evaluated that i...
Will Hanmi Pharm start to develop modified drug of ‘Evista’?Hanmi Pharm is about to jump in the development of incrementally modified drug of Evista(generic name: raloxifene), an osteoporosis therapy.
Hanmi Pharm was confirmed to file a...
|
Pharmaceutical exports doubled up for past 4 years, Yuhan and Hanmi exceeding KRW 1 trillion sales
Exports related to the healthcare industry, such as drugs, were known to enlarge double for the past 4 years. Sales of listed companies specializing in pharmaceutical products and medical device were increased last ye...
Hanmi Science’s M&A on ‘JVM’ through investing KRW 129 billion
On the 9th, the holding company of Hanmi Pharm, Hanmi Science(CEO Jong-yoon Lim) officially announced the M&A of JVM, a global company in the automated medication management system field, through the stock swapping me...
